Article

PDT laser receives expedited review status

The FDA has accepted for filing and granted expedited review status to the Miravant Medical Technologies' premarket application for the IRIS Medical OcuLight 664 ophthalmic photodynamic therapy (PDT) laser used to activate drug SnET2, a proposed drug and light treatment for patients with wet age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
Related Content
FDA approves Lenz Therapeutics’ VIZZ for the treatment of presbyopia
July 31st 2025

FDA approves Lenz Therapeutics’ VIZZ for the treatment of presbyopia

3 Things You Should Know About the GA Pipeline
July 31st 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: A VERONA trial update with Yasha S. Modi, MD
July 31st 2025

Q&A: A VERONA trial update with Yasha S. Modi, MD

Patient-Centered Treatment Strategies in the Management of nAMD and DME
July 31st 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Opus Genetics partners with Global RDH12 Alliance
July 31st 2025

Opus Genetics partners with Global RDH12 Alliance

(Image credit: Wills Eye Hospital) Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer
July 31st 2025

Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer

© 2025 MJH Life Sciences

All rights reserved.